ArticleScientific reports2026
Early hepatitis B and delta virus kinetics in patients undergoing liver transplantation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
HBV recurrence after liver transplantation (LT) can occur despite removal of the infected liver and antiviral prophylaxis. Timing and mechanisms of HBV and HDV recurrence remain unclear. We evaluated post-transplant viral kinetics to address this gap. Twelve HBV patients undergoing LT, including five with HDV-coinfection, were prospectively enrolled. Serial serum and liver samples were rigorously collected before, during, and post-LT to characterize viral kinetics. HBV-DNA, HDV-RNA, HBsAg, and HDAg were detected in all explanted livers, whereas cccDNA was found only in HBV-monoinfected patients. Serum HBV-DNA, detectable in five recipients before LT, became undetectable within hours from LT. In HBV-monoinfected patients, baseline HBsAg levels were low (< 3logIU/mL) and cleared rapidly after LT, with faster disappearance in those receiving HBIG (5 days vs. 6 months). Among HDV-recipients, all treated with HBIG, HBsAg clearance was rapid when baseline HBsAg levels were <3log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.